500
Participants
Start Date
December 30, 2023
Primary Completion Date
November 22, 2024
Study Completion Date
December 30, 2025
atherolive-drug
The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
Placebo Atherolive
The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
RECRUITING
University Hospital Fattouma Bourguiba Monastir, Monastir
University of Monastir
OTHER